Business Of Biotech Lessons From The Bone Therapeutics/Medsenic Merger With BioSenic's François Rieger, Ph.D.
Mar 20, 2023
Chapters
Transcript
Episode notes
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
Introduction
00:00 • 2min
Dr. Regier: How to Pronouce French
01:34 • 2min
The Importance of Transitioning to Industry
03:10 • 3min
The Importance of Basic Science in Emerging and Clinical Stage Biopharma
05:56 • 2min
The Problem With the Growth of Biopharma Companies
07:36 • 2min
The Origin Story of Biosonic
09:51 • 4min
The Importance of Bone Tarpetics in Chronic Diseases
13:30 • 5min
The Politics of Big Firms
18:57 • 2min
The Challenges of Fundraising a Merger
21:23 • 2min
The Mechanics of the Acquisition
23:42 • 2min
The Importance of Contacting the Top Management of Biotech Leaders
26:05 • 4min
The Reverse Merger of Metzemic and Bone Therapeutics
30:32 • 2min
Biocenic's General Assembly of Bone Therapeutics
32:40 • 2min
How to Merge Medsenic and Bone Therapeutics Together
35:04 • 4min
The Batic Science Culture
39:33 • 2min
The Importance of Synergizing Systems and Technologies
41:36 • 3min
The Impact of the Merger on the Biosonic Therapeutic Development
44:47 • 4min
The Future of Bontalapetics
49:10 • 2min
The Pros and Cons of the Acquisition
51:32 • 2min
Biosonic CEO Dr. Francois Rijer: What Should Rest?
53:03 • 3min